StockData
Eloxx Pharmaceuticals, Inc. logo

Eloxx Pharmaceuticals, Inc. (ELOX) shareholders

ELOXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 7/30
$11.74−1.01 (-7.92%)

Close on Nov 17, 2026Market cap $79.70MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
71.8%
3M of 4M shares
Institutional holders
22
22 new, 0 sold out
Net institutional buying
3M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Coastlands Capital GP LLC
Joint filing with Coastlands Capital LP (16.51%), Coastlands Capital Partners LP (16.51%) and 2 more
1,250,00016.15%13G (passive)Apr 27, 2026
Domicilium Capital Partners LLC
Joint filing with Daniel Simon (19.99%), Bkjlagg, LLC (14.10%) and 4 more
854,97319.99%13G (passive)Jun 5, 2026
Coastlands Capital Partners LP
Joint filing with Coastlands Capital LP (9.99%), Coastlands Capital GP LLC (9.99%) and 2 more
410,5309.99%13G (passive)Jun 10, 2026
Raymond Debbane
Joint filing with Invus Public Equities, L.P. (8.80%), Invus Public Equities Advisors, LLC (8.80%) and 2 more
403,5869.99%13G (passive)Jun 9, 2026
EcoR1 Capital, LLC
Joint filing with Oleg Nodelman (9.90%), EcoR1 Capital Fund Qualified, L.P. (9.30%)
403,5869.90%13G (passive)Jun 9, 2026
Srinivas Akkaraju
Joint filing with Samsara BioCapital, L.P. (5.00%), Samsara BioCapital GP, LLC (5.00%) and 2 more
403,5869.90%13G (passive)Jun 10, 2026
Stonepine Capital, L.P.
Joint filing with Stonepine Capital Management, LLC (9.90%), Stonepine GP, LLC (9.90%) and 1 more
403,2289.90%13G (passive)Jun 9, 2026
Nantahala Capital Management, LLC
Joint filing with Wilmot B. Harkey (9.91%), Daniel Mack (9.91%)
400,0009.91%13G (passive)Jun 30, 2026
Aberdeen Group plc
Joint filing with abrdn Inc. (9.91%)
400,0009.91%13G (passive)Jun 30, 2026

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of ELOXValueChange% of portfolio
Nantahala Capital Management, LLC800,00019.82%$11.10MNew0.18%
abrdn plc400,0009.91%$5.55MNew0.01%
EcoR1 Capital, LLC400,0009.91%$5.55MNew0.27%
Samsara BioCapital, LLC400,0009.91%$5.55MNew0.46%
Siren, L.L.C.400,0009.91%$5.55MNew0.11%
Stonepine Capital Management, LLC397,1609.84%$5.51MNew3.11%
Vanguard Capital Management LLC78,6801.95%$1.09MNew0.00%
Vanguard Fiduciary Trust Co10,6020.26%$147.16KNew0.00%
Seven Grand Managers, LLC10,0000.25%$138.80KNew0.01%
Morgan Stanley1,5440.04%$21.43KNew0.00%
Vanguard Global Advisers, LLC7180.02%$9.97KNew0.00%
UBS Group AG6370.02%$8.84KNew0.00%
Wells Fargo & Company/Mn1260.00%$1.75KNew0.00%
Royal Bank of Canada980.00%$1.00KNew0.00%
Pioneer Family Office, LLC960.00%$1.33KNew0.00%
Altshuler Shaham Ltd250.00%$347New0.00%
Barclays PLC120.00%$167New0.00%
Old Point Trust & Financial Services N A50.00%$69New0.00%
Activest Wealth Management40.00%$56New0.00%
Citigroup Inc40.00%$56New0.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 2026223M71.8%22 / 00 / 03M0M
Q1 202300M0.0%0 / 00 / 10M0M
Q4 202210M0.4%0 / 10 / 310M0M
Q3 2022320M7.8%3 / 69 / 20M0M
Q2 2022320M8.1%3 / 513 / 70M0M
Q1 2022360M9.3%3 / 814 / 60M0M
Q4 2021390M10.3%10 / 913 / 120M0M
Q3 2021410M10.0%8 / 1212 / 140M0M
Q2 2021470M10.3%22 / 1010 / 130M0M
Q1 2021380M5.4%1 / 913 / 40M0M
Q4 2020410M5.4%4 / 159 / 10M0M
Q3 2020380M5.3%1 / 717 / 30M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

7 funds held ELOX in Q3 2023, 57% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of ELOXValue% of fundAs of
Vanguard Total Stock Market Index Fund57,4761.42%$797.77K0.00%Jun 30, 2026
Vanguard Extended Market Index Fund19,2910.48%$267.76K0.00%Jun 30, 2026
Vanguard Balanced Index Fund1,0360.03%$14.38K0.00%Jun 30, 2026
Vanguard Institutional Total Stock Market Index Fund8770.02%$12.17K0.00%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Sumit AggarwalPresident and CEO, Director1,672,75641.44%Jun 10, 2026
Geno J. GermanoDirector––Oct 21, 2026
Nina S. KjellsonDirector––Jun 10, 2026
Steven D. RubinDirector14,6250.36%Jun 10, 2026
Stephen W. WebsterDirector––Jun 10, 2026
Alan Edmund WaltsDirector15,5670.39%Jun 10, 2026
Lindsay AndroskiDirector15,7500.39%Jan 28, 2025
Real Estate Fund III LP Domicilium10% owner238,4225.91%Jun 17, 2026
Capital LP Coastlands10% owner0–May 29, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Real Estate Fund III LP Domicilium
10% owner
Jun 10, 2026Other+238,422––238,422
Real Estate Fund III LP Domicilium
10% owner
Jun 10, 2026Other+361,578––361,578
Real Estate Fund III LP Domicilium
10% owner
May 27, 2026Other−113,636––0
Capital LP Coastlands
10% owner
May 27, 2026Other−1,250,000––0
Sumit Aggarwal
President and CEO, Director, 10% owner
Feb 28, 2026Option exercise+260,946$0.15$39.14K1,672,756
Steven D. Rubin
Director
Jan 24, 2026Option exercise+1,875––14,625
Alan Edmund Walts
Director
Jan 24, 2026Option exercise+1,875––15,567
Sumit Aggarwal
President and CEO, Director, 10% owner
Jan 24, 2026Option exercise+15,000––1,411,810
Sumit Aggarwal
President and CEO, Director, 10% owner
Sep 19, 2025Award+1,000,000––1,396,810
Sumit Aggarwal
President and CEO, Director, 10% owner
Aug 14, 2025Option exercise+196,880––396,810
Lindsay Androski
Director
Jan 24, 2025Option exercise+3,750––15,750
Sumit Aggarwal
Director
Jan 24, 2025Option exercise+30,000––199,930
Steven D. Rubin
Director
Jan 24, 2025Option exercise+3,750––15,750
Alan Edmund Walts
Director
Jan 24, 2025Option exercise+3,750––16,692
Lindsay Androski
Director
Oct 16, 2024Award+12,000––12,000
Steven D. Rubin
Director
Oct 16, 2024Award+12,000––12,000
Alan Edmund Walts
Director
Oct 16, 2024Award+12,000––12,942
Sumit Aggarwal
PRESIDENT AND CEO, Director
Oct 16, 2024Award+165,000––169,930
Vijay Modur
HEAD OF R&D
Dec 1, 2021Option exercise+219,326––219,326
Vijay Modur
HEAD OF R&D
Dec 1, 2021Tax withholding−64,373$0.72$46.35K154,953
Sumit Aggarwal
PRESIDENT AND CEO, Director
Dec 1, 2021Tax withholding−81,933$0.72$58.99K197,225
Sumit Aggarwal
PRESIDENT AND CEO, Director
Dec 1, 2021Option exercise+279,158––279,158
Alan Edmund Walts
Director
Dec 1, 2021Option exercise+37,695––37,695
Daniel E. Geffken
INTERIM CFO
Nov 29, 2021Buy+50,000$0.72$36.00K50,000
Neil S. Belloff
COO, GENERAL COUNSEL &CORP SEC
Jul 30, 2021Option exercise+1,563––33,158
Neil S. Belloff
COO, GENERAL COUNSEL &CORP SEC
Jul 30, 2021Tax withholding−459$1.32$60632,699
Neil S. Belloff
COO, GENERAL COUNSEL &CORP SEC
May 25, 2021Option exercise+6,250––33,430
Neil S. Belloff
COO, GENERAL COUNSEL &CORP SEC
May 25, 2021Tax withholding−1,835$1.39$2.55K31,595
Management 4 G.P. (2015) Ltd. Pontifax
10% owner
May 13, 2021Buy+1,280,624$1.35$1.73M1,791,470
Management 4 G.P. (2015) Ltd. Pontifax
10% owner
May 13, 2021Buy+2,630,487$1.35$3.55M3,679,797
Management 4 G.P. (2015) Ltd. Pontifax
10% owner
May 13, 2021Buy+1,422,222$1.35$1.92M1,989,551
Management 4 G.P. (2015) Ltd. Pontifax
10% owner
May 13, 2021Buy+592,592$1.35$800.00K616,592
Tomer Kariv
Director
May 13, 2021Buy+592,592$1.35$800.00K616,592
Tomer Kariv
Director
May 13, 2021Buy+1,422,222$1.35$1.92M1,989,551
Tomer Kariv
Director
May 13, 2021Buy+2,630,487$1.35$3.55M3,679,797
Tomer Kariv
Director
May 13, 2021Buy+1,280,624$1.35$1.73M1,791,470
Rajesh B. Parekh
Director
May 13, 2021Buy+2,381,890$1.35$3.22M4,827,129
Rajesh B. Parekh
Director
May 13, 2021Buy+84,776$1.35$114.45K171,807
Ran Nussbaum
Director
May 13, 2021Buy+1,280,624$1.35$1.73M1,791,470
Ran Nussbaum
Director
May 13, 2021Buy+2,630,487$1.35$3.55M3,679,797
Ran Nussbaum
Director
May 13, 2021Buy+1,422,222$1.35$1.92M1,989,551
Ran Nussbaum
Director
May 13, 2021Buy+592,592$1.35$800.00K616,592
Neil S. Belloff
COO, GENERAL COUNSEL &CORP SEC
Apr 30, 2021Tax withholding−459$2.18$1.00K27,180
Neil S. Belloff
COO, GENERAL COUNSEL &CORP SEC
Apr 30, 2021Option exercise+1,562––27,639
Rajesh B. Parekh
Director
Apr 1, 2021Award+2,445,239––2,445,239
Rajesh B. Parekh
Director
Apr 1, 2021Award+87,031––87,031
Neil S. Belloff
COO, GENERAL COUNSEL &CORP SEC
Feb 25, 2021Tax withholding−7,338$3.95$28.99K26,077
Neil S. Belloff
COO, GENERAL COUNSEL &CORP SEC
Feb 25, 2021Option exercise+25,000––33,415
Gregory C. Williams
CHIEF EXECUTIVE OFFICER, Director
Feb 25, 2021Tax withholding−15,360$3.95$60.67K44,629
Gregory C. Williams
CHIEF EXECUTIVE OFFICER, Director
Feb 25, 2021Option exercise+50,000––59,989
Neil S. Belloff
COO, GENERAL COUNSEL &CORP SEC
Jan 30, 2021Tax withholding−542$3.44$1.86K8,415
Neil S. Belloff
COO, GENERAL COUNSEL &CORP SEC
Jan 30, 2021Option exercise+1,563––8,957
Gregory C. Williams
CHIEF EXECUTIVE OFFICER, Director
Jan 30, 2021Tax withholding−643$3.44$2.21K9,989
Gregory C. Williams
CHIEF EXECUTIVE OFFICER, Director
Jan 30, 2021Option exercise+1,875––10,632
Gregory C. Williams
CHIEF EXECUTIVE OFFICER, Director
Oct 30, 2020Tax withholding−625$2.53$1.58K8,757
Gregory C. Williams
CHIEF EXECUTIVE OFFICER, Director
Oct 30, 2020Option exercise+1,875––9,382
Neil S. Belloff
COO, GENERAL COUNSEL &CORP SEC
Oct 30, 2020Tax withholding−459$2.53$1.16K7,394
Neil S. Belloff
COO, GENERAL COUNSEL &CORP SEC
Oct 30, 2020Option exercise+1,562––7,853
Neil S. Belloff
COO, GENERAL COUNSEL &CORP SEC
Jul 30, 2020Tax withholding−459$2.84$1.30K6,291
Neil S. Belloff
COO, GENERAL COUNSEL &CORP SEC
Jul 30, 2020Option exercise+1,563––6,750

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
2.27%
0M shares short
Days to cover
2.1
At 0M shares a day
Change since last report
+27.2%
From 0M shares
Short volume, 20 days
49.1%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Eloxx Pharmaceuticals's stock actually held short. Settlement fails (shares not delivered on time) peaked at 2,418 shares on Sep 14, 2026 over the last 90 days.

See a number that looks wrong?